International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis - Wikidata - awgldk - TriplyDB

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

http://www.wikidata.org/entity/Q34536278

about

TNF-alpha inhibitors for ankylosing spondylitis Exercise therapy for ankylosing spondylitis TNF-alpha inhibitors for ankylosing spondylitis 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis Comparison of performance of the Assessment of SpondyloArthritis International Society, the European Spondyloarthropathy Study Group and the modified New York criteria in a cohort of Chinese patients with spondyloarthritis Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.Anti-TNF-alpha therapy in ankylosing spondylitis.Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.Rheumatology and musculoskeletal medicine Discovertebral (Andersson) lesions in severe ankylosing spondylitis: a study using MRI and conventional radiography.Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: results of an international survey Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.Update on the treatment of ankylosing spondylitis.Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.Established criteria for disease controlling drugs in ankylosing spondylitis.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.ASAS/EULAR recommendations for the management of ankylosing spondylitis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany.LLLT for the management of patients with ankylosing spondylitis.The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis?Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 A novel gene variation of TNFalpha associated with ankylosing spondylitis: a reconfirmed study Body mass index influences the response to infliximab in ankylosing spondylitis Elevated serum interleukin-23 levels in ankylosing spondylitis patients and the relationship with disease activity.

P2860

Q24186462-95952EA3-3B79-4F9E-835B-32A136140FFB Q24193372-9808C11B-CC4C-45F0-B722-D3F5C82F16EF Q24246757-FA5553D7-20C8-4DC3-ACCC-ACB8AEF0CF29 Q24603648-F5A94FF3-16E5-45DA-AFD8-C0745770603E Q24604766-5F8C443C-456F-4248-8AFD-773DB3E08A85 Q24816557-04563A86-86BB-4FAD-9408-66AE67B10340 Q30239856-1287542B-E936-46A9-A476-705F103ABA56 Q30413598-073EFE14-228E-49B3-A322-8C17C47842B3 Q33204138-09F3400C-8E2E-4F7D-876C-16A87058098C Q33923298-2B7514BD-8116-498B-B67E-DBCABDB4A423 Q34098905-15E62B6F-B036-4E0C-9205-564A849BF7FF Q34268747-C9873D19-2201-4F4E-B9E8-24544CFBF86C Q34570459-A4AA2A4D-628D-4C25-A6E6-BBDD4044CE50 Q34570563-E8C16197-5325-4946-9705-4FC1AA3AE7D6 Q34592673-53BC14C8-DCE7-4DB2-8DC4-0C1F6EBECCAB Q34896269-168FFC9D-56FF-425B-A754-955B59C87B2A Q35098611-708DF4BB-02F5-479B-A0F9-281202382738 Q35553086-5289A6D7-4C84-46BF-997C-412B472465EC Q35553451-682F9A95-570C-477E-B2A4-E14D7985A07E Q35553607-113D4CB5-AE8B-4C4F-8B29-D40EF2AD28F0 Q35554218-C7ABC945-F196-49E5-9D8D-81851A82DFA3 Q35554918-9347F968-E7D4-4A36-8F9B-841E3FD9FFA0 Q35557859-16E0C131-B669-4599-8AD7-86AB451FF221 Q35579352-4D792ACF-F165-4612-9A64-5A1C62250909 Q35579517-8573DD8A-EC95-4A4E-81A2-D861E5479F92 Q35636708-3A633221-A454-4498-81CD-AB9313323A09 Q35636900-D0C1B90D-D9CC-453E-86EF-FA7E1CB8363B Q35637012-9287AF8F-96AF-4291-BDC2-A2698C69C6E7 Q35638252-53F77CFF-76E7-4C81-8D15-4B27CCB41F88 Q35638572-3FD2CA75-16E9-48E6-86A4-47E7859CB167 Q35851000-3F252814-A8A4-48CB-860E-D60FBAFA0CD2 Q35900547-7F86E6C2-3AA2-4FC2-BAA9-E4B698373D7F Q35953515-54CE6CFB-AE98-4953-87E2-171DBBD03C39 Q35954616-C0477A1F-BEB6-4EA8-8680-0DED764975CD Q36040018-76C8598A-A590-4D7D-AE2E-EF7F939ED3F7 Q36059338-50C2582D-E939-4AF9-B426-4F3F48736FC0 Q36171750-1B790E5B-5FF4-4F8C-BBF6-0B7BC1D7D496 Q36204130-E45DBD90-C30B-455F-84A4-521AEE90E0B4 Q36245977-4DA14DBA-36C1-4296-AD04-4B883FE775EB Q36332633-E1E0A56D-DE73-495B-8831-60268EB5FF29

P2860

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

http://www.wikidata.org/entity/Q34536278

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

International ASAS consensus s ...... ts with ankylosing spondylitis

@ast

International ASAS consensus s ...... ts with ankylosing spondylitis

@en

International ASAS consensus s ...... ts with ankylosing spondylitis

@nl

type

label

International ASAS consensus s ...... ts with ankylosing spondylitis

@ast

International ASAS consensus s ...... ts with ankylosing spondylitis

@en

International ASAS consensus s ...... ts with ankylosing spondylitis

@nl

prefLabel

International ASAS consensus s ...... ts with ankylosing spondylitis

@ast

International ASAS consensus s ...... ts with ankylosing spondylitis

@en

International ASAS consensus s ...... ts with ankylosing spondylitis

@nl

P1433

Q34536278-F3514E73-6216-4565-899C-7507CD445FC9

P1476

Q34536278-DAE088D1-AE66-4A89-91E9-44D570EFC442

P2093

Q34536278-2F0A43E8-2D86-4DD1-ADC2-174B4544B940

Q34536278-529E629F-E52A-48A3-B1BD-550CB80EF521

Q34536278-5A6E873C-BF8C-482D-9AD5-3C1FBB84B14D

Q34536278-CAE82D78-2575-4698-B914-1A4466BAE51B

Q34536278-E2469A62-C1E4-4EA3-8DCE-2EFD1856B64F

Q34536278-F00CE299-E38D-42E6-B8EE-C6F986D3B00A

Q34536278-F44AF5DB-039D-4F14-8682-1FBD9B93486E

P2860

Q34536278-1CABAEE1-2B5B-40A2-A751-E535E4134D2C

Q34536278-2C069035-988D-4A2C-932E-E68046B88340

Q34536278-2C7A3A96-9E01-4BCA-9250-2E5E1D3AC15F

Q34536278-2D271D8B-37FD-4603-A8D0-89FC115E16B6

Q34536278-320613E9-F39D-4B12-B357-AECE8A67BA6A

Q34536278-39CAF4D3-12ED-483E-946A-69B8BEBC012E

Q34536278-40D9504A-D89D-4D89-825E-BF117AA605C9

Q34536278-449D3DF0-8A88-49AA-987F-E8A4F79F59F4

Q34536278-4E6B9E1E-AE95-4E93-B085-43E32FB7807D

Q34536278-53D90296-E6B2-4E81-9FC8-226EB91CFE70

P304

Q34536278-2F2BFEF5-F86B-4983-ABC4-0A955D8D5E52

P31

Q34536278-10DE5D3A-2D7B-480D-8868-50847673BCDA

P356

Q34536278-D70EC2BE-A76D-4FD1-8202-8C5232BA6A9F

P407

Q34536278-C23A3D32-E436-49DF-B670-4523113B4E10

P433

Q34536278-2B52AB49-6A4B-4488-9AAF-7DA81F0981FA

P478

Q34536278-1F96DB0D-F3F6-4463-B643-B22FFD8ECF80

P50

Q34536278-BDFB8950-2717-42C3-B8DD-EA47652A9DB9

P577

Q34536278-D2C6C578-8634-4564-AE45-E61D8BE47010

P5875

Q34536278-A6E35327-64B0-4A06-9C8D-02D35468F985

P698

Q34536278-6D513430-0BF3-4DBC-A8DF-FE558153A6FF

P921

Q34536278-C0E504D0-3127-43C5-9052-DD61CCC1D543

Q34536278-d8c09f85-c769-495c-af8f-960b8f923bd4

P932

Q34536278-CFFE012D-C522-4F74-A4BC-EB2CDBBAFD1E

P356

P1433

Annals of the Rheumatic Diseases

P1476

International ASAS consensus s ...... ts with ankylosing spondylitis

@en

P2093

ASAS Working Group

http://www.w3.org/2001/XMLSchema#string

J Braun

http://www.w3.org/2001/XMLSchema#string

J Davis

http://www.w3.org/2001/XMLSchema#string

J Sieper

http://www.w3.org/2001/XMLSchema#string

M Dougados

http://www.w3.org/2001/XMLSchema#string

Sj van der Linden

http://www.w3.org/2001/XMLSchema#string

T Pham

http://www.w3.org/2001/XMLSchema#string

P2860

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis.

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.

Mortality, course of disease and prognosis of patients with ankylosing spondylitis.

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

P304

817-824

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.62.9.817

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Désirée van der Heijde

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10610122

http://www.w3.org/2001/XMLSchema#string

P698

12922952

http://www.w3.org/2001/XMLSchema#string

P921

P932

1754665

http://www.w3.org/2001/XMLSchema#string